President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Through House Bill 1489, the state would establish a trade commission with Ireland to strengthen its business relationship ...

Dividend-screened portfolios of various kinds have failed to keep up with the broad US stock market over the past 10 years, ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today ...

With this funding, TMCF can begin new partnerships and investments that further their mission for HBCUs' sustainable futures.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.